SCHEMBL5207734

SCHEMBL5207734

Cc1[nH]c(C2CCC(CNC3CCCC3)CC2)nc1-c1cccc(C(F)(F)F)c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KIT P10721 8/20 0.51
CSNK1A1 P48729 1/20 0.45
CSNK1D P48730 1/20 0.45
RPS6KA3 P51812 1/20 0.45
ADORA1 P30542 1/20 0.45
MAPK13 O15264 4/20 0.42
MAPK9 P45984 4/20 0.42
MAPK12 P53778 4/20 0.42
MAPK11 Q15759 4/20 0.42
MAPK14 Q16539 4/20 0.42
RAF1 P04049 2/20 0.40
KDM1A O60341 1/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
GRIN1 Q05586 1/20 0.40
GRIN2B Q13224 1/20 0.40
PIM1 P11309 2/20 0.39
TP53 P04637 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5205607 0.84 KIT (0.51) KITCSNK1A1CSNK1DRPS6KA3ADORA1
SCHEMBL5202721 0.81 KDM1A (0.44) CSNK1A1CSNK1DRPS6KA3ADORA1KDM1A
SCHEMBL5206636 0.78 KIT (0.49) KITCSNK1A1CSNK1DRPS6KA3ADORA1
SCHEMBL15732412 0.70 KIT (0.52) KITCSNK1A1CSNK1DRPS6KA3ADORA1
SCHEMBL5211402 0.69 PIN1 (0.52) ADORA1MAPK13MAPK9MAPK12MAPK11
SCHEMBL5206571 0.68 VCP (0.43) KITCSNK1A1CSNK1DRPS6KA3ADORA1
SCHEMBL5203558 0.67 VCP (0.47) CSNK1A1CSNK1DRPS6KA3MAPK13MAPK9
SCHEMBL5205247 0.66 VCP (0.45) KDM1AMAOAMAOBPIM1
SCHEMBL13608179 0.64 GRIN1 (0.48) ADORA1GRIN1GRIN2B
SCHEMBL5202973 0.64 VCP (0.45) KDM1AMAOAMAOBGRIN1GRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1306085-B1 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor NEUROGEN CORP (US) 2007-02-14 EP disclosed
US-7034034-B2 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives NEUROGEN CORPORATION (US) 2006-04-25 US disclosed
WO-2003104255-A2 SUBSTITUTED 2-CYCLOHEXYL-4-PHENYL-1H-IMIDAZOLE DERIVATIVES NEUROGEN CORPORATION (US) 2003-12-18 WO disclosed
US-20030144290-A1 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives NEUROGEN CORPORATION 2003-07-31 US disclosed
EP-1306085-A1 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor Neurogen Corporation (US) 2003-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144290-A1 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives NPY5R, NPY4R, NPY1R KIT 1906/4885CSNK1A1 2040/4885CSNK1D 1185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.